Acurx Pharmaceuticals, Inc.

NASDAQ:ACXP

0.7 (USD) • At close January 14, 2025
Bedrijfsnaam Acurx Pharmaceuticals, Inc.
Symbool ACXP
Munteenheid USD
Prijs 0.699
Beurswaarde 13,626,096
Dividendpercentage 0%
52-weken bereik 0.68 - 5
Industrie Biotechnology
Sector Healthcare
CEO Mr. David P. Luci CPA, CPA, Esq., J.D.
Website https://www.acurxpharma.com

An error occurred while fetching data.

Over Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing

Vergelijkbare Aandelen

Precipio, Inc. logo

Precipio, Inc.

PRPO

6.06 USD

Healthcare Triangle, Inc. logo

Healthcare Triangle, Inc.

HCTI

0.938 USD

Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc.

RVPH

1.58 USD

Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc.

MRKR

2.54 USD

GeoVax Labs, Inc. logo

GeoVax Labs, Inc.

GOVX

2.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)